HC Wainwright reaffirmed their buy rating on shares of AzurRx BioPharma (NASDAQ:AZRX) in a report issued on Friday, AnalystRatings.com reports.
“Our price target is derived from a market value of the firm at $189M, which includes a discounted cash flow-based asset value of $190M for MS1819, using a 15% discount rate and 2% terminal growth rate, excluding debt, with 50% probability of success.”,” the firm’s analyst commented.
Other equities analysts have also issued research reports about the company. Maxim Group reissued a buy rating and issued a $5.00 target price on shares of AzurRx BioPharma in a research report on Wednesday, April 24th. Oppenheimer set a $8.00 target price on AzurRx BioPharma and gave the stock a buy rating in a research report on Tuesday, February 26th. Finally, Roth Capital started coverage on AzurRx BioPharma in a research report on Friday, January 25th. They issued a buy rating and a $10.50 target price for the company. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company has an average rating of Buy and a consensus target price of $7.30.
AZRX opened at $2.16 on Friday. AzurRx BioPharma has a 1 year low of $1.00 and a 1 year high of $3.75.
A number of large investors have recently modified their holdings of AZRX. 683 Capital Management LLC raised its position in AzurRx BioPharma by 73.9% in the 4th quarter. 683 Capital Management LLC now owns 695,504 shares of the company’s stock worth $842,000 after buying an additional 295,504 shares during the last quarter. Waldron Private Wealth LLC purchased a new position in AzurRx BioPharma in the 1st quarter worth about $169,000. J. Goldman & Co LP raised its position in AzurRx BioPharma by 4.9% in the 1st quarter. J. Goldman & Co LP now owns 578,398 shares of the company’s stock worth $1,400,000 after buying an additional 27,040 shares during the last quarter. Regentatlantic Capital LLC purchased a new position in AzurRx BioPharma in the 1st quarter worth about $48,000. Finally, Vanguard Group Inc raised its position in AzurRx BioPharma by 2.1% in the 3rd quarter. Vanguard Group Inc now owns 413,439 shares of the company’s stock worth $1,063,000 after buying an additional 8,489 shares during the last quarter. 13.12% of the stock is owned by institutional investors and hedge funds.
About AzurRx BioPharma
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
Recommended Story: How to Use a Moving Average for Trading
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.